About this item:

167 Views | 78 Downloads

Author Notes:

Corresponding author: Dong M. Shin dmshin@emory.edu.

See publication for full list of authors.

The authors thank Jeff Lewis (M.D. Anderson Cancer Center), Nicole Kluz, Alicia Wentz (Johns Hopkins School of Public Health); Rachel Moreno (Emory University) for data collection, and Dr. Anthea Hammond for critical reading and editing of the manuscript.

Subjects:

Research Funding:

The study was supported by the NCI Head and Neck Cancer SPORE Consortium Supplement (3P50DE019032–14S1).

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Otorhinolaryngology
  • Surgery
  • biomarkers
  • head and neck cancer
  • human immunodeficiency virus (HIV)
  • prognosis
  • survival
  • HIV-INFECTED PATIENTS
  • AIDS-DEFINING CANCERS
  • ANTIRETROVIRAL THERAPY
  • CIGARETTE-SMOKING
  • NEXT-GENERATION
  • UNITED-STATES
  • HPV INFECTION
  • IMMUNE CELLS
  • RISK-FACTORS
  • INFLAMMATION

Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma

Show all authors Show less authors

Tools:

Journal Title:

Head and Neck

Volume:

Volume 39, Number 12

Publisher:

, Pages 2433-2443

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Background: We examined the prognostic value of a panel of biomarkers in patients with squamous cell carcinoma of the head and neck (SCCHN) who were human immunodeficiency virus (HIV) positive (HIV-positive head and neck cancer) and HIV negative (HIV-negative head and neck cancer). Methods: Tissue microarrays (TMAs) were constructed using tumors from 41 disease site-matched and age-matched HIV-positive head and neck cancer cases and 44 HIV-negative head and neck cancer controls. Expression of tumor biomarkers was assessed by immunohistochemistry (IHC) and correlations examined with clinical variables. Results: Expression levels of the studied oncogenic and inflammatory tumor biomarkers were not differentially regulated by HIV status. Among patients with HIV-positive head and neck cancer, laryngeal disease site (P =.003) and Clavien-Dindo classification IV (CD4) counts <200 cells/μL (P =.01) were associated with poor prognosis. Multivariate analysis showed that p16 positivity was associated with improved overall survival (OS; P <.001) whereas increased expression of transforming growth factor-beta (TGF-β) was associated with poor clinical outcome (P =.001). Conclusion: Disease site has significant effect on the expression of biomarkers. Expression of tumor TGF-β could be a valuable addition to the conventional risk stratification equation for improving head and neck cancer disease management strategies.

Copyright information:

© 2017 Wiley Periodicals, Inc.

Export to EndNote